Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions
Alzheimer DiseaseParkinson DiseaseHealthy Volunteers
Interventions
DRUG

[18F]MNI-1126

"Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures."

Trial Locations (1)

06510

Invicro, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Invicro

OTHER